Download PDF
Thromb Haemost 1970; 24(01/02): 033-042
DOI: 10.1055/s-0038-1654208
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Fibrinolytic Activation of Plasma by Means of Urokinase in Vitro and in Vivo

L. B Nanninga
1   Department of Physiology, University of Texas Medical Branch, Galveston, Texas
,
M. M Guest   *
1   Department of Physiology, University of Texas Medical Branch, Galveston, Texas
› Author Affiliations
Further Information

Publication History

Publication Date:
28 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

The activation of plasma by urokinase was studied in vitro by measuring the levels of fibrinogen, the anticoagulant split product of fibrinogen and the level of profibrinolysin. It is concluded that normal plasma contains about one CTA unit of plasmakinase, expressed in urokinase equivalents. The level of free fibrinolysin after complete activation of profibrinolysin was estimated to be approximately one-tenth of the initial profibrinolysin concentration. The split product of fibrinogen is present as an intermediate in a consecutive reaction in amounts dependent on the concentration of the activator present.

* Supported by U.S.P.H.S. Grant HE 10893.


 

  • References

  • 1 Nanninga L. B, Guest M. M. Antifibrinolytic action of the anticoagulant split product of fibrinogen. Thrombos. Diathes. haemorrh. (Stuttg) 19: 526 1968;
    PubMedSearch in Google Scholar
  • 2 Maxwell R. E, Nickel V. S, Lewandowski V. Preparations of plasminogen deficient fibrinogen and thrombin. Biochem. biophys. Res. Commun 07: 50 1962;
    CrossrefPubMedSearch in Google Scholar
  • 3 Nanninga L. B, Guest M. M. Activity-pH relationship and Michaelis constants during activation of profibrinolysin and during fibrinogenolysis. Thrombos. Diathes. haemorrh. (Stuttg) 19: 492 1968;
    PubMedSearch in Google Scholar
  • 4 Ware A. J, Guest M. M, Seegers W. H. Fibrinogen; with special reference to its preparation and certain properties of the product. Arch. Biochem 13: 231 1947;
    PubMedSearch in Google Scholar
  • 5 Nanninga L. B, Guest M. M. Preparation and properties of the anticoagulant split product of fibrinogen and its determination in plasma. Thrombos. Diathes. haemorrh. (Stuttg) 17: 440 1967;
    PubMedSearch in Google Scholar
  • 6 Nanninga L. B. Rapid determination of profibrinolysin (plasminogen) in plasma. Thrombos. Diathes. haemorrh. (Stuttg) 17: 8 1967;
    PubMedSearch in Google Scholar
  • 7 Robbins K. C, Summaria L, Hsieh B, Shah R. J. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J. biol. Chemistry 242: 2333 1967;
    PubMedSearch in Google Scholar
  • 8 Nanninga L. B, Guest M. M. Rapid determination of antifibrinolysin (antiplasmin) in plasma. Thrombos. Diathes. haemorrh 15: 273 1966;
    PubMedSearch in Google Scholar
  • 9 Schwick H. G. Biochemie der Fibrinolyse. Thrombos. Diathes. haemorrh. (Stuttg) 17, Suppl 22: 28 1967;
    PubMedSearch in Google Scholar
  • 10 Norman SPh. Studies on the plasmin system. I. Measurement of human and animal plasminogen. Measurement of an activator in human serum. J. exp. Med 106: 423 1957;
    PubMedSearch in Google Scholar
  • 11 Fletcher A. P, Alkjaersig N, Sherry S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (fibrinolytic) states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. J. clin. Invest 41: 896 1962;
    PubMedSearch in Google Scholar
  • 12 Amris A, Amris C. J. Turnover and distribution of 131iodine labelled human fibrinogen. Thrombos. Diathes. haemorrh. (Stuttg) 11: 404 1964;
    PubMedSearch in Google Scholar
  • 13 Hart C. hH, Meeuwissen T. hOJA. La demi-vie biologique du fibrinogène marqué a l’aide d’iode radioactif (I131) dans les cas d’hypercholesterolémie et d’affections vasculaires arterielles. Coagulation 01: 71 1968;
    PubMedSearch in Google Scholar
  • 14 Ferguson E. W. Effects of exercise and physical conditioning on hemostatic mechanisms. Thesis, University of Texas Medical Branch; Galveston, Texas, 1969.:
  • 15 Schwick H. G. Immunochemistry of fibrinogen. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl 13: 85 1964;
    PubMedSearch in Google Scholar
  • 16 Das P. G, Allan A. G. E, WoocLfield D. G, Gash J. D. Fibrin degradation products in sera of normal subjects. Brit. med. J 1967; part 4, 718.
    PubMedSearch in Google Scholar
  • 17 Latallo Z. S, Fletcher A. P, Alkjaersig N, Sherry S. Inhibition of fibrin polymerization by fibrinogen proteolysis products. Amer. J. Physiol 202: 681 1962;
    PubMedSearch in Google Scholar
  • 18 Bang N. U, Fletcher A. P, Alkjaersig N, Sherry S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (fibrinolytic) states. III. Demonstration of abnormal clot structure by electron microscopy. J. clin. Invest 41: 935 1962;
    PubMedSearch in Google Scholar
  • 19 Nolf P. Des modifications de la coagulation du sang chez le chien après extirpation du foie. Arch. int. Physiol 03: 1 1905;
    PubMedSearch in Google Scholar
  • 20 Astrup T. In: Connective Tissue, Thrombosis and Atherosclerosis. Page I. H. editor. Academic Press; 1959: 224.
    Search in Google Scholar
  • 21 Copley A. L. In: Flow Properties of Blood. Ed. Copley A. L, Stainsby G. Pergamon Press; 1960
    Search in Google Scholar
  • 22 Gitlin D, Borges W. H. Studies on the metabolism of fibrinogen in two patients’with congenital afibrinogenemia. Blood 08: 679 1953;
    PubMedSearch in Google Scholar
  • 23 Nanninga L. B, Guest M. M, Dickie K. J, de Groot W. J, Bond T. The appearance of fibrinogen derivatives in thromboembolic disease after treatment with urokinase. XII Congress International Soc. of Hematology. New York: 1968
    Search in Google Scholar
  • 24 Niléhn J. E. Split products of fibrinogen after prolonged interaction with plasmin. Thrombos. Diathes. haemorrh. (Stuttg) 18: 89 1967;
    PubMedSearch in Google Scholar